UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ~~______________________~~ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 23, 2013 Tanke Biosciences Corporation (Exact name of registrant as specified in its charter)

Date of Report (Date of earliest event reported): February 9, 2013

Tanke Biosciences Corporation (Exact name of registrant as specified in its charter)

Nevada		000-53529		26-3853855
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Room 2801, East Tower of Hui Hao Building, No. 519 Machang Road Pearl River New City, Guangzhou, People’s Republic of China		510627
Room 2801, East Tower of Hui Hao Building, No. 519 Machang Road, Pearl River New City, Guangzhou, People’s Republic of China		510627
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +86-20-38859025

N/A (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

~~Check~~This ~~the~~Current ~~appropriate~~Report ~~box~~on ~~below if the~~ Form 8-K ~~filing~~includes ~~is intended to simultaneously satisfy~~ the ~~filing~~following ~~obligation~~items ofon ~~the~~Form ~~registrant under any of the following provisions~~8-K:

¨Item ~~Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230~~1.~~425) ¨¨¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240~~01.~~14a-12)~~ Entry ~~¨¨¨~~into ~~Pre-commencement~~a ~~communications~~Material ~~pursuant~~Definitive ~~to Rule 14d-2(b) under the Exchange Act (17 CFR 240~~Agreement.~~14d-2(b)) ¨¨¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))~~

On February 9, 2011, in connection with the closing of the transactions described in Item 23.0402 ~~Triggering~~of ~~Events~~our ~~That~~Current ~~Accelerate~~Report oron ~~Increase~~Form 8-K filed February 9, 2011, Tanke Biosciences Corporation (formerly known as Greyhound Commissary, Inc.) (the “Company”) entered into a ~~Direct~~Securities ~~Financial~~Purchase ~~Obligation~~Agreement or(the an“Securities ~~Obligation~~Purchase ~~under~~Agreement”) with the purchasers identified on Schedule A thereto (each, including their respective successors and assigns, an ~~Off~~“Investor” and collectively, the “Investors”) and, with respect to certain sections thereof, Euro Pacific Capital, Inc. (the “Lead Placement Agent”) and Newbridge Securities Corporation (the “Co-~~Balance~~Placement ~~Sheet~~Agent”), ~~Arrangement~~relating to a private placement by the Company (the “Private Placement”) of 6,669,627 units (the “Units”), with each Unit consisting of a $1.15 principal amount 8% Senior Convertible Note (each, a “Note” and collectively the “Notes”) and a Common Stock Purchase Warrant (each, a “Warrant” and collectively the “Warrants”) to purchase one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”) with an exercise price of $1.40 per share.

~~Default~~Pursuant ~~under~~to ~~Senior~~the ~~Convertible~~Securities Purchase Agreement, the Company and the holders of the Notes (each a “Holder” and collectively the “Holders”) duly appointed Euro Pacific Capital, Inc. to serve as Investor Representative (the “Investor Representative”) for the Holders of the Notes, and as such Holders’ true and lawful agent and attorney-in-fact to, among other matters, waive any terms and conditions of the Notes and to be such Holders’ exclusive representative with respect to any matter, suit, claim, action or proceeding arising with respect to any transaction contemplated by the Notes and the Warrants.

AsIn ofconnection ~~February~~with ~~10,~~the ~~2013,~~Securities ~~Tanke~~Purchase ~~Biosciences~~Agreement, ~~Corporation (~~the “Company”) isentered ininto ~~default~~a ~~under~~Registration ~~the~~Rights ~~terms~~Agreement ~~of the Company’s 8% Senior Convertible Notes~~ (the “~~Senior~~Registration ~~Convertible~~Rights ~~Notes~~Agreement”) ~~issued~~with ~~to certain accredited investors (~~the ~~“Investors”).~~Holders ~~The~~which ~~default~~sets isforth the ~~result~~rights of the ~~Company’s~~Holders ~~failure~~ to ~~pay~~have totheir ~~the~~shares ~~Investors~~of ~~approximately~~Common ~~$7.67~~Stock ~~million~~underlying inthe ~~principal~~Notes ~~plus accrued interest due~~ and ~~payable on February 9, 2013 under~~ the ~~terms~~Warrants of(and ~~the~~certain ~~Senior~~other ~~Convertible~~securities ~~Notes. The~~as ~~Company~~described ~~has~~below) ~~agreed~~registered towith ~~release $230,000 held in escrow to~~ the ~~Investors,~~Securities ofand ~~which~~Exchange ~~$68,178~~Commission ~~will be used to pay Investors all remaining accrued interest, and~~ (the ~~balance~~“SEC”) ~~shall~~for bepublic ~~applied towards the principal~~resale.

The ~~Senior~~Registration ~~Convertible~~Rights ~~Notes~~Agreement ~~were~~provides ~~issued~~that in ~~connection~~the ~~with~~event the ~~Securities~~Registration ~~Purchase~~Statement ~~Agreement~~has ~~(the~~not ~~“Securities~~been ~~Purchase~~filed ~~Agreement”),~~or ~~dated~~declared aseffective ofwithin ~~February~~the 9,prescribed ~~2011,~~time ~~between~~period ~~the~~or ~~Company~~if ~~and~~ the ~~Investors~~Company ~~and,~~has ~~with~~failed ~~respect~~ to ~~certain~~maintain ~~sections~~the effectiveness of the ~~Securities~~Registration ~~Purchase~~Statement ~~Agreement~~as required, ~~Euro~~the ~~Pacific~~Company ~~Capital,~~shall ~~Inc.~~pay (to the ~~“Investor~~Investors ~~Representative”)~~liquidated ~~and~~damages ~~Newbridge~~equal ~~Securities~~to ~~Corporation,~~1.0% ~~relating~~of to the ~~offering~~amount ofinvested ~~6,669,627~~for ~~units~~each atsubsequent a30-day ~~purchase~~period ~~price~~until ofthe ~~$1.15~~Company ~~per~~cures ~~unit. Each~~the ~~unit~~failure ~~consisted~~to offile, ago ~~$1.15~~effective ~~principal~~or ~~amount~~maintain 8%effectiveness, ~~Senior~~as ~~Convertible~~applicable, ~~Note~~up ~~and~~to a ~~common~~maximum ~~stock~~of ~~purchase~~6.0%, ~~warrant~~and toprorated ~~purchase~~for ~~one~~any ~~share~~period of ~~the~~less ~~Company’s~~than ~~common~~30 ~~stock,~~days. ~~with~~(the an“Registration ~~exercise~~Delay ~~price of $1.40 per share.~~Payments”)

AsThe aCompany ~~result~~currently ofowes the ~~Company’s~~Holders ~~failure~~Registration toDelay ~~pay~~Payments ~~all~~in ~~amounts due and payable under~~ the ~~Senior~~approximate ~~Convertible~~aggregate ~~Notes~~amount as of ~~February 9~~$460,206 ~~2013,~~(as ~~all~~accrued ~~obligations~~on of the Company’s ~~under~~balance ~~the~~sheet ~~Senior~~in ~~Convertible~~2011) ~~Notes~~as ~~shall~~a beresult ~~immediately~~of ~~due and payable and~~ the ~~Investors~~Company’s ~~may~~failure ~~exercise~~to ~~any~~register ~~other remedies~~ the ~~Investors~~shares ~~may~~of ~~have~~the ~~under~~Company’s ~~the~~common ~~transaction~~stock ~~documents,~~issuable atupon ~~law~~the orconversion inof ~~equity~~the Notes.

~~The~~On ~~Company~~August is23, ~~currently~~2013, inthe ~~discussion~~Company ~~with~~and the Investor Representative ~~and~~for ~~Investors~~the ~~regarding~~Holders ~~proposals~~of ~~relating~~Notes toentered ~~the~~in ~~Senior~~amendment ~~Convertible~~to the Notes ~~and~~ (the ~~Company’s~~“Amendment”). ~~default~~Pursuant ~~thereunder,~~to ~~including~~Section a2 ~~repayment~~of ~~schedule~~the ~~for~~Amendment, the ~~remaining~~Company ~~principal.~~has ~~Attached~~agreed asto ~~Exhibit~~pay ~~99.1~~the isoutstanding aprincipal ~~letter~~amount toof the ~~Investors~~Notes ~~from~~as ~~the Company’s Chief Financial Officer, Gilbert Lee.~~follows:

~~Item~~· ~~9.01~~$1 ~~Financial~~million ~~Statements~~as soon as practical and ~~Exhibits.~~in any event prior to September 30, 2013;

~~(d)~~· ~~Exhibits~~$1 million on or before December 31, 2013;

Exhibit
Number	Description
99.1	Letter, dated February 13, 2013, to Investors that invested in the Company’s February 9, 2011 financing.

·	$1,500,000 on or before June 30, 2014

·	$1,500,000 on or before December 31, 2014

·	The balance of the outstanding principal amount of approximately $2,510,000 on or before March 31, 2015

Pursuant to Section 3 of the Amendment, the Holders agreed to waive their right to receive such Registration Delay Payments. The parties further agreed that as soon as the Company makes the first principal payment on or before September 30, 2013, the Company may write off the accrued payable of $460,206 from its balance sheet. However, if the Company fails to make the first principal payment of $1 million on or before September 30, 2013, the full amount of $460,206 of the Registration Delay Payment shall once again become due immediately and payable notwithstanding the waiver.

Further, interest on the principal balance of the Note shall no longer accrue so long as the Company makes principal payments in accordance with Section 2 of the Note Amendment. If the Company fails to make a principal payment in accordance with Section 2 of the Amendment, and such failure is not cured within 45 days, then interest will be deemed to have accrued on the entire unpaid principal balance retroactively from the then missed payment due date and interest shall continue to accrue thereafter until the unpaid principal balance and all accrued interest thereon has been paid in full. In such case, interest on the then outstanding principal balance shall accrue at the rate of eight percent (8%) per annum.

On February 9, 2011, the Company, Golden Genesis Limited, a British Virgin Islands company (the “Pledgor”), the Investment Representative, and Escrow LLC (the “Escrow Agent”) entered into a Securities Escrow Agreement. Pursuant to Section 4 of the Amendment, the Company acknowledges on behalf of itself and on behalf of its affiliate, the Pledgor, the Company’s and Pledgor’s obligation to deliver to the Holders, on a pro rata basis in the aggregate, 500,000 shares (the “Pledged Shares”) of the Company’s Common Stock that are being held by the Escrow Agent. The Pledged Shares shall be delivered to the Holders on or before September 30, 2013. The failure to deliver the Pledged Shares on or before September 30, 2013 shall be deemed to be the equivalent of a failure to make a scheduled principal payment under Section 2 of the Amendment and, accordingly, interest will begin to accrue on the unpaid principal balance of the Notes from and after September 30, 2013. The other 500,000 non-voting shares shall remain in escrow and shall be reverted to the Pledgor when the Company completely pays off the Notes. If the Company fails to make a principal payment in accordance with Section 2 and does not cure such breach within forty-five (45) days, these remaining 500,000 shares shall be immediately issued to the Holders.

Exhibit Number		Description of Exhibit

Exhibit 10.1		Amendment to Promissory Notes, dated as of August 23, 2013

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 13, 2013	TANKE BIOSCIENCES CORPORATION
Date: August 29, 2013	TANKE BIOSCIENCES CORPORATION
	By:	/s/ Guixiong Qiu
		Name:	Guixiong Qiu
		Title:	Chief Executive Officer

Filing Compare · Tanke Biosciences Corp